Skip to main content
Erschienen in: Cancer Causes & Control 4/2009

01.05.2009 | Brief Report

Maximizing resources to study an uncommon cancer: E2C2—Epidemiology of Endometrial Cancer Consortium

verfasst von: Sara H. Olson, Chu Chen, Immaculata De Vivo, Jennifer A. Doherty, Virginia Hartmuller, Pamela L. Horn-Ross, James V. Lacey Jr., Shannon M. Lynch, Leah Sansbury, V. Wendy Setiawan, Leo J. Schouten, Xiao Ou Shu

Erschienen in: Cancer Causes & Control | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Endometrial cancer affects more than 40,000 women a year in the U.S. While the association of this disease with high body mass index and sex steroid hormones is well known, there are many questions about etiology that have not been resolved. Little is known about the genetic basis for risk associated with hormones or obesity, other common genetic factors associated with risk, or gene–environment interactions. E2C2, the Epidemiology of Endometrial Cancer Consortium, was formed in 2006 to provide a collaborative environment for addressing these questions by pooling data from existing studies. This allows for investigations of uncommon risk factors, risk for rare histologic subtypes, and associations within strata that cannot be achieved in individual studies. This report describes the establishment of the consortium, ongoing projects that demonstrate the advantages of collaborative efforts, and challenges faced. Overall, the consortium promises to provide an important means of furthering our knowledge about this cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat American Cancer Society (2008) Cancer facts and figures 2008. American Cancer Society, Atlanta American Cancer Society (2008) Cancer facts and figures 2008. American Cancer Society, Atlanta
2.
Zurück zum Zitat Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57(2):205–212PubMed Key TJ, Pike MC (1988) The dose-effect relationship between ‘unopposed’ oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 57(2):205–212PubMed
3.
4.
Zurück zum Zitat Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108(3):425–432. doi:10.1002/ijc.11529 PubMedCrossRef Lukanova A, Lundin E, Micheli A, Arslan A, Ferrari P, Rinaldi S et al (2004) Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int J Cancer 108(3):425–432. doi:10.​1002/​ijc.​11529 PubMedCrossRef
5.
Zurück zum Zitat Zheng W, Chow WH, Yang G, Jin F, Rothman N, Blair A, Li HL, Wen W, Ji BT, Li Q, Shu XO, Gao YT (2005) The Shanghai Women’s Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol 162(11):1123–1131. doi:10.1093/aje/kwi322 PubMedCrossRef Zheng W, Chow WH, Yang G, Jin F, Rothman N, Blair A, Li HL, Wen W, Ji BT, Li Q, Shu XO, Gao YT (2005) The Shanghai Women’s Health Study: rationale, study design, and baseline characteristics. Am J Epidemiol 162(11):1123–1131. doi:10.​1093/​aje/​kwi322 PubMedCrossRef
6.
Zurück zum Zitat Kolonel LN, Altshuler D, Henderson BE (2004) The Multiethnic Cohort Study: exploring genes, lifestyle and cancer risk. Nat Rev 4(7):519–527 Kolonel LN, Altshuler D, Henderson BE (2004) The Multiethnic Cohort Study: exploring genes, lifestyle and cancer risk. Nat Rev 4(7):519–527
7.
Zurück zum Zitat Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D et al (2003) A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 12(20):2679–2692. doi:10.1093/hmg/ddg294 PubMedCrossRef Haiman CA, Stram DO, Pike MC, Kolonel LN, Burtt NP, Altshuler D et al (2003) A comprehensive haplotype analysis of CYP19 and breast cancer risk: the Multiethnic Cohort. Hum Mol Genet 12(20):2679–2692. doi:10.​1093/​hmg/​ddg294 PubMedCrossRef
8.
11.
Zurück zum Zitat Olson SH, Orlow I, Bayuga S, Sima C, Bandera EV, Pulick K et al (2008) Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control. Apr 25 (Epub ahead of print) Olson SH, Orlow I, Bayuga S, Sima C, Bandera EV, Pulick K et al (2008) Variants in hormone biosynthesis genes and risk of endometrial cancer. Cancer Causes Control. Apr 25 (Epub ahead of print)
12.
Zurück zum Zitat Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G et al (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 67(5):1893–1897. doi:10.1158/0008-5472.CAN-06-4123 PubMedCrossRef Haiman CA, Dossus L, Setiawan VW, Stram DO, Dunning AM, Thomas G et al (2007) Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res 67(5):1893–1897. doi:10.​1158/​0008-5472.​CAN-06-4123 PubMedCrossRef
13.
Zurück zum Zitat Setiawan VW, Doherty JA, Shu X, Akbari MR, Chen C, De Vivo I et al (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in E2C2. Cancer Epidemiol Biomarkers Prev 18(1):242–247PubMedCrossRef Setiawan VW, Doherty JA, Shu X, Akbari MR, Chen C, De Vivo I et al (2009) Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in E2C2. Cancer Epidemiol Biomarkers Prev 18(1):242–247PubMedCrossRef
14.
Zurück zum Zitat Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN (1997) Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 146(4):294–306PubMed Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN (1997) Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 146(4):294–306PubMed
15.
Zurück zum Zitat Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM (2003) Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst 95(15):1158–1164PubMedCrossRef Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM (2003) Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst 95(15):1158–1164PubMedCrossRef
16.
Zurück zum Zitat Xu WH, Dai Q, Xiang YB, Long JR, Ruan ZX, Cheng JR et al (2007) Interaction of soy food and tea consumption with CYP19A1 genetic polymorphisms in the development of endometrial cancer. Am J Epidemiol 7(12):1420–1430. doi:10.1093/aje/kwm242 CrossRef Xu WH, Dai Q, Xiang YB, Long JR, Ruan ZX, Cheng JR et al (2007) Interaction of soy food and tea consumption with CYP19A1 genetic polymorphisms in the development of endometrial cancer. Am J Epidemiol 7(12):1420–1430. doi:10.​1093/​aje/​kwm242 CrossRef
17.
Zurück zum Zitat Sherman ME, Sturgeon S, Brinton LA, Potischman N, Kurman RJ, Berman ML et al (1997) Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 10(10):963–968PubMed Sherman ME, Sturgeon S, Brinton LA, Potischman N, Kurman RJ, Berman ML et al (1997) Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 10(10):963–968PubMed
18.
19.
Zurück zum Zitat World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington, DC World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington, DC
Metadaten
Titel
Maximizing resources to study an uncommon cancer: E2C2—Epidemiology of Endometrial Cancer Consortium
verfasst von
Sara H. Olson
Chu Chen
Immaculata De Vivo
Jennifer A. Doherty
Virginia Hartmuller
Pamela L. Horn-Ross
James V. Lacey Jr.
Shannon M. Lynch
Leah Sansbury
V. Wendy Setiawan
Leo J. Schouten
Xiao Ou Shu
Publikationsdatum
01.05.2009
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 4/2009
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9290-y

Weitere Artikel der Ausgabe 4/2009

Cancer Causes & Control 4/2009 Zur Ausgabe

Letter to the Editor

Authors’ reply

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.